Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer

Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
Metastatic thyroid cancers that are refractory to radioiodine (iodine-131) are associated with a poor prognosis. In mouse models of thyroid cancer, selective mitogen-activated protein kinase (MAPK) pathway antagonists increase the expression of the sodium …
Read more on The New England Journal of Medicine